Michael Campbell

发表

An in vitro toolbox to accelerate anti-malarial drug discovery and development

David M. Shackleford, Dennis A. Smith, S. Charman, 2020, Malaria Journal.

3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.

J. Baell, V. Avery, S. Charman, 2013, European journal of medicinal chemistry.

Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease

David M. Shackleford, M. J. Abbott, Paul W. Alexander, 2013, Journal of medicinal chemistry.

A novel multiple-stage antimalarial agent that inhibits protein synthesis

David W. Gray, E. Winzeler, S. Meister, 2015, Nature.

A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.

David M. Shackleford, R. Price, P. Rathod, 2016, ACS infectious diseases.

Simplified Silvestrol Analogues with Potent Cytotoxic Activity

David C. S. Huang, J. Chambers, J. White, 2014, ChemMedChem.

Discovery and Structure–Activity Relationships of Pyrrolone Antimalarials

Ian H. Gilbert, Marcel Kaiser, David M. Shackleford, 2013, Journal of medicinal chemistry.

Degradation of berenil (diminazene aceturate) in acidic aqueous solution

R. Prankerd, W. Charman, Michael Campbell, 2004, The Journal of pharmacy and pharmacology.

Mechanisms of action of novel skin penetration enhancers: phospholipid versus skin lipid liposomes.

G. E. El Maghraby, B. Finnin, Michael Campbell, 2005, International journal of pharmaceutics.

Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis

James A Daniel, R. Parton, F. Meunier, 2013, Traffic.

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

Christian Scheurer, Lukas Stingelin, David M. Shackleford, 2011, Proceedings of the National Academy of Sciences.

Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins.

C. Porter, W. Charman, M. Mcintosh, 2004, Journal of Controlled Release.

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

E. Winzeler, S. Meister, J. Rayner, 2016, Nature.